# A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations

> **NCT02950064** · PHASE1 · UNKNOWN · sponsor: **Placon Therapeutics** · enrollment: 95 (estimated)

## Conditions studied

- Pancreatic Neoplasms
- Ovarian Neoplasms
- Breast Neoplasms
- Prostatic Neoplasms

## Interventions

- **DRUG:** BTP-114

## Key facts

- **NCT ID:** NCT02950064
- **Lead sponsor:** Placon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2020-04
- **Final completion:** 2020-08
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02950064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02950064, "A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02950064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*